KESSLER TOPAZ MELTZER & CHECK, LLP – Reminds Investors of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
194
KESSLER TOPAZ MELTZER & CHECK, LLP – Reminds Investors of Securities Fraud Class Action Lawsuit Against VALARIS PLC – VAL

RADNOR, Pa., Sept. 06, 2019 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern District of New York against Valaris plc (NYSE:  VAL) (“Valaris”) on behalf of those who purchased or otherwise acquired Valaris securities between April 11, 2019 and July 31, 2019 , inclusive (the “Class Period”).

Important Deadline:   Investors who purchased Valaris securities during the Class Period may, no later than October 21, 2019 , seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please visit www.ktmc.com/valaris-plc-securities-class-action .

According to the complaint, Valaris provides offshore drilling services in various water depths worldwide, operating a rig fleet of ultra-deepwater drillships, versatile semisubmersibles, and modern shallow-water jackups. Valaris’ offshore fleet includes sixteen drillships, twelve semisubmersibles, fifty-four jackups, and two deepwater managed units. Prior to the Class Period, Valaris was known as Ensco plc (“Ensco”). 

The Class Period commences on April 11, 2019, when Ensco issued a press release, pre-market, announcing the completion of the merger of Ensco and Rowan Companies plc (“Rowan”) into Ensco Rowan plc (“Ensco Rowan”).  The press release touted, among other things, Ensco Rowan’s “diverse rig fleet of ultra-deepwater drillships, versatile semisubmersibles and modern shallow-water jackups” that purportedly enabled Ensco Rowan “to provide drilling services across all water depths with unmatched scale, geographic presence and customer relationships.” The press release also contained statements by top-level management which touted the financial strength and growth opportunities generated by the Ensco Rowan merger. On July 2, 2019, Ensco Rowan announced that it would change its name to Valaris plc, effective July 31, 2019. 

According to the complaint, on July 31, 2019, Valaris issued a press release announcing its second quarter 2019 financial results—purportedly its first earnings report post-merger reflecting the results of the combined company—which missed market expectations. Upon issuance of the press release, analysts at Seeking Alpha published an article on August 2, 2019, entitled “Valaris PLC - Off To A Bad Start”, and noted that Valaris’ results “shock[ed] investors with massive cash usage [and] . . . surprisingly weak outlook for the ultra-deepwater segment with further dayrate recovery likely delayed until at least the second half of next year.” The article further criticized Valaris’ free cash flow for the quarter, which was “negative by a whopping $375 million causing the company’s remaining pro forma cash balance adjusted for roughly $741 million in payments related to the recent debt tender offer to decline to just $353 million.” 

Following this news, Valaris’ stock price fell $3.25 per share, or approximately 39%, over the two trading sessions following its announcement of its quarterly financial results, to close at $5.02 per share on August 2, 2019. 

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) Valaris was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on Valaris’ second quarter 2019 results; (iii) the merger leading to Valaris’ establishment could not deliver on its touted benefits; and (iv) as a result, Valaris’ public statements were materially false and misleading at all relevant times.

If you wish to discuss this securities fraud class action lawsuit or have any questions concerning this notice or your rights or interests with respect to this litigation, please contact Kessler Topaz Meltzer & Check (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (844) 887-9500 (toll free) or (610) 667–7706, or via e-mail at info@ktmc.com .

Valaris investors may, no later than October 21, 2019 , seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member.  A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.  The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).  The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com .

CONTACT:

Kessler Topaz Meltzer & Check, LLP James Maro, Jr., Esq. Adrienne Bell, Esq. 280 King of Prussia Road Radnor, PA 19087 (844) 887-9500  (toll free) (610) 667-7706 info@ktmc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 421

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 281

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 34

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 536

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 462

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 547

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 308

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 243

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Silexion Therapeutics to Showcase Innovations at Upcoming Conference

Updated Category News Views 127

Silexion Therapeutics and Its Future in Oncology Silexion Therapeutics Corp. is at the forefront of the biotechnology sector, focusing its efforts on innovative treatments specifically designed for oncology. This clinical-stage company is dedicated to transforming the landscape for patients with hard-to-treat cancers, primarily those with the mutated KRAS oncogene, known...

Continue Reading
UBS Predicts Slowdown in Nvidia-Led Tech Rally - Key Insights

Updated Category News Views 172

UBS Foresees Changes in Tech Rally Dynamics Analysts at UBS suggest that the excitement surrounding the recent tech rally, driven by Nvidia, is beginning to wane. They predict a shift towards a more volatile market environment, influenced by ongoing economic challenges and increasing regulatory scrutiny in the semiconductor sector. Analysts' Perspectives on Future Stock...

Continue Reading
OS Therapies (OSTX) Unveils Encouraging Survivorship Data

Updated Category News Views 222

OS Therapies Inc. Reports Promising Results in Bone Cancer Therapy OS Therapies Inc. (NYSE: OSTX), a company focused on developing innovative cancer treatments, recently reported compelling findings from its Phase 2b clinical trial on OST-HER2, an off-the-shelf immunotherapy designed for addressing osteosarcoma, a challenging form of bone cancer. Significant Survival Data...

Continue Reading
Jeito Capital Boosts Aviceda Therapeutics with $207.5M Funding

Updated Category News Views 239

Jeito Capital's Strategic Investment in Aviceda Therapeutics Jeito Capital has recently announced a significant investment in Aviceda Therapeutics, securing a substantial participation in an upsized $207.5 million Series C financing round aimed at advancing the company's lead program, AVD-104. This funding is specifically intended to support pivotal trials for AVD-104,...

Continue Reading
Apple's Innovative M4 Mac Mini Sets New Standards in Tech

Updated Category News Views 293

Apple Launches the Game-Changing Mac Mini Apple Inc (NASDAQ: AAPL) has once again captivated technology enthusiasts and consumers alike with its latest innovation — the redesigned Mac mini equipped with groundbreaking M4 and M4 Pro chips. This launch not only showcases Apple's commitment to performance but also its pioneering approach to sustainability, marking the Mac...

Continue Reading